



NPR

Natural products in soil microbe interactions and evolution.

Journal:	<i>Natural Product Reports</i>
Manuscript ID:	NP-REV-02-2015-000013.R1
Article Type:	Review Article
Date Submitted by the Author:	11-May-2015
Complete List of Authors:	Traxler, Matthew; University of California at Berkeley, Plant and Microbial Biology Kolter, Roberto; Harvard Medical School, Microbiology and Immunobiology

SCHOLARONE™
Manuscripts

1 **Natural products in soil microbe interactions and evolution.**

2

3

Matthew F. Traxler² and Roberto Kolter^{1*}

4

5

6

7 ¹Dept. of Microbiology and Immunobiology, Harvard Medical School, Boston,
8 Massachusetts 02115

9 ²Dept. of Plant and Microbial Biology, University of California at Berkeley, Berkeley,
10 California 94720

11

12 Email: mtrax@berkeley.edu

13

14 * Corresponding author: Roberto Kolter

15 Department of Microbiology and Immunobiology

16 Harvard Medical School

17 Boston, MA 02115

18 Email: rkolter@hms.harvard.edu

19

20 Short summary: In recent years, bacterial interspecies interactions mediated by small molecule
21 natural products have been found to give rise to a surprising array of phenotypes in soil-dwelling
22 bacteria, especially among *Streptomyces* and *Bacillus* species. This review examines these
23 interspecies interactions, and the natural products involved, as they have been presented in
24 literature stemming from four disciplines: soil science, interspecies microbiology, ecology, and
25 evolutionary biology. We also consider how these interactions fit into accepted paradigms of
26 signaling, cueing, and coercion.

27
28

- 29 **1. Natural products from bacteria**
- 30 **2. Life in the soil**
- 31 **3. Actinomycete interactions**
- 32 **3A. Actinomycete biology**
- 33 **3B. Interactions involving antibiotic production**
- 34 **3C. Interactions involving siderophores**
- 35 **3D. Frequency of interactions between actinomycetes**
- 36 **4. Interactions involving *Bacillus***
- 37 **4A. Interactions that alter *B. subtilis* biofilm formation**
- 38 **4B. Natural products in *B. subtilis* interactions**
- 39 **5. Natural products in the evolutionary context of soil microbes**
- 40 **5A. Are antibiotics signaling molecules?**
- 41 **5B. Competition and evolutionary costs of specialized metabolism**
- 42 **6. Concluding remarks**
- 43 **7. References**

44
45

46 **1. Natural products from bacteria**

47

48 Bacteria have given us a truly marvelous bounty of bioactive small molecules. These
49 natural products have been a pillar of modern medicine since the middle of last century. Often
50 referred to as secondary, or 'specialized' metabolites, a number of these compounds have
51 been the frontline therapy against bacterial infections. The remarkable success of the first
52 antibiotics, prime among them penicillin and streptomycin, prompted a worldwide search for
53 useful antibiotics that peaked in the 1960s. The fruit of this search was a myriad of useful
54 compounds from bacteria including antibiotics, anti-cancer drugs, immunosuppressants,
55 antifungals, and anthelmintics.

56

57 Thus far, the overwhelming majority of bacterial natural products discovered come from
58 organisms that inhabit the soil. The soil plays host to a rich and diverse community of bacteria.
59 Among these, organisms known as actinomycetes have been the richest source of specialized
60 metabolites¹⁻³. While the term 'actinomycete' is in fact not a formal phylogenetic designation, it is
61 conventionally used to describe any filamentous, Gram positive actinobacterium from the soil,
62 including those of the most prolific genus *Streptomyces*. However, numerous other bacteria
63 from the soil also produce natural products including those of the phylum *Firmicutes* (e.g.
64 *Bacillus*). More recently, it has become evident that organisms from the phylum *Proteobacteria*,
65 specifically those in the order *Myxococcales* have complex specialized metabolisms as well⁴.

66

67 The post-genomic era has witnessed renewed interest in the discovery of natural
68 products from bacteria, including actinomycetes. Specifically, as genome sequences from
69 multiple actinomycetes became available, a new and exciting trend emerged. While most
70 actinomycetes sequenced thus far produce only one or two useful compounds, virtually every

71 actinomycete genome contains gene clusters for the synthesis of ten, twenty, or even thirty
72 natural products that have never been characterized^{5, 6}. These 'cryptic' gene clusters constitute
73 a vast resource that humans have yet to effectively tap into. In fact, it is estimated that only 1-
74 3% of antibiotics from streptomycetes have been discovered, and the percentage is even lower
75 for other 'rare' actinomycetes⁷. Thus, these organisms still hold great potential as a source of
76 new natural products. However, a key challenge remains: how do we gain access to these
77 compounds if they are not produced under standard laboratory conditions? And, even beyond
78 this, why are these gene clusters 'silent' in the first place? These questions belie the fact that we
79 remain profoundly ignorant regarding the ecological context in which these small molecules are
80 made, how they function in natural settings, or how they evolved.

81
82 Since the early days of antibiotics discovery, it was hypothesized that these compounds
83 might be made to allow the producing organism to defend its resources or territory against
84 would-be invaders⁸. More recently, the possibility that these molecules might function as
85 signaling molecules has begun to be explored⁹⁻¹². In either case, the underlying assumption is
86 that these natural products likely mediate interactions between microorganisms, possibly
87 between members of the same species, or across species lines. The past several years have
88 seen a rapid expansion in the number of studies examining bacterial interspecies interactions,
89 both as a means for understanding the ecological role of specialized metabolites, and a
90 potential way to discover novel natural products.

91
92 In this review we examine recent advances brought about by studying interspecies
93 interactions between soil bacteria with an emphasis on actinomycetes and members of the
94 genus *Bacillus*. We examine the involvement of natural products in mediating these interactions,
95 and instances where novel metabolites have been discovered. We also give special
96 consideration to interactions that influence complex bacterial behaviors, including biofilm
97 formation and multicellular development. As actinomycetes and *Bacillus* are indigenous to the
98 soil, we begin by considering what life is like in this environment and how natural products might
99 interact with soil particles. We go on to consider the strategies and contingencies that might
100 drive natural product evolution and function in the soil environment.

101 2. Life in the soil

102
103 The soil is a remarkably complex and dynamic environment. It holds a vast amount of
104 metabolically active biomass from all three kingdoms of life¹³⁻¹⁶. A single gram of soil can
105 contain $\sim 10^9$ bacteria, $\sim 10^6$ fungi, $\sim 10^3$ protozoa, $\sim 10^2$ nematodes, as well as annelids and
106 arthropods¹³. The majority of this biomass is microbial, and the activity of these microbes plays
107 a key role in multiple geochemical cycles, including the carbon and nitrogen cycles. Given the
108 immense scope of the microbial soil community, it is perhaps not surprising that the genetic
109 diversity present in soil is correspondingly vast. This likely reflects the fact that soil is
110 heterogeneous at scales ranging from kilometers to micrometers^{17, 18}. It is at this microscopic
111 scale that microbes interact with the soil and other soil inhabitants¹⁹.

112
113
114 The soil itself is a highly porous mixture of minerals and organic matter, and its
115 composition is spatially and temporally variable. In a 'typical' handful of topsoil, only about 50%
116 of its volume is solid (e.g. composed of organic and inorganic material), the remainder is air and
117 water-filled space that occupies the areas between and within individual grains of soil¹⁵. This
118 porosity results in a tremendous amount of surface area, although the fraction colonized by
119 bacteria is placed at less than 1%¹³. Several lines of evidence suggest that microbial activity can
120 influence particle aggregation, resource flow, and hydraulic conductivity (water movement)
121 within soil environments^{18, 20}. Recently, it was also shown that filamentous bacteria might be

122 able to bridge air-filled gaps between soil particles better than their unicellular counterparts,
123 especially when water content of the soil is low. Conversely, when moisture levels were higher,
124 motile bacteria spread faster through soil compared to filamentous bacteria²¹.

125
126 While a few studies have begun to look at the physical distribution of bacteria in soil ^{19, 22},
127 the autofluorescent nature of soil, combined with its inherent heterogeneity has made arriving at
128 a clear understanding of how bacteria are distributed within this environment difficult to
129 achieve¹⁵. However, techniques such as x-ray tomography, combinatorial labeling and spectral
130 imaging with fluorescent *in-situ* hybridization (CLASI-FISH), and thin sectioning of soil particles
131 have the best potential to shed light on the spatial organization of bacterial soil communities^{15, 23}.
132 With such limited information, we can only hypothesize about what the structure of colonies of
133 bacteria, including those that produce natural products, might be in soil microenvironments. It
134 seems likely that such colonies might contain a relatively small number of bacterial cells (or
135 filaments, in the case of actinomycetes), a situation that is very different from colonies of these
136 organisms when they are grown on solid laboratory medium¹⁹.

137
138 How do small molecules, like natural products, diffuse in soil? Observation of natural
139 product biosynthesis by a single microcolony of bacteria in a soil microenvironment has never
140 been achieved. However, as antibiotics are widely used in human populations for medical
141 reasons, and as growth enhancers in livestock production, some effort has been made to
142 understand the fate of these molecules in the environment²⁴, including how they interact with
143 soils. The bioavailability of natural products is determined by their sorption behavior, *i.e.* their
144 propensity to partition to the solid (soil) phase or the aqueous phase *in situ* (reviewed in ²⁵). Key
145 environmental factors including the soil pH and the ratio of clay to organic material present in
146 the soil also influence the sorption behavior of natural products^{25, 26}. For example, tetracycline,
147 an antibiotic made by many species of streptomycetes, is freely soluble in water, but is very
148 efficiently (over 96%) sorbed by soil, especially the clay component²⁶. This sorption is somewhat
149 reduced by organic soil material (*e.g.* humic substances) and by increasing pH²⁶. The fact that
150 an antibiotic like tetracycline, which is completely soluble in water, is so efficiently retained by
151 soil may imply that antibiotic diffusion away from producing organisms is limited in a soil
152 microenvironment.

153
154 We also note that in actinomycetes, biosynthesis of many antibiotics is autoregulated via
155 the action of secreted signaling molecules, typically γ -butyrolactones²⁷⁻³³. Regulation by these
156 extracellular 'autoregulatory factors' may insure that antibiotic production will not occur unless a
157 critical mass of mycelium is present. The implication being that antibiotic production will not
158 ensue unless the population is sufficient to make a 'meaningful' amount of antibiotics³⁴⁻³⁷.
159 Presumably this means a concentration of molecules sufficient to achieve an evolutionarily
160 advantageous effect. Taken together, limited diffusion in the soil environment and the
161 extracellular control of antibiotic production suggests to us that it is plausible that relatively high
162 (*i.e.* inhibitory) concentrations of natural products might be achieved in the immediate vicinity of
163 the microenvironments inhabited by these bacteria.

164 165 **3. Actinomycete interactions**

166
167 **A. Actinomycete biology:** Actinomycete bacteria were first found in bone growths caused by
168 'lumpy jaw' in cattle in the 1870s, but by the early part of the 20th century they were recognized
169 as a commonplace component of soil microbial communities³⁸. At that time, they were regarded
170 as a third major group of soil inhabitants, and a possible intermediate between fungi and
171 bacteria³⁹. This was because actinomycete colonies had features of both fungi and bacteria.
172 Like some fungi, their colony surfaces appeared fuzzy due to their hyphal growth. But their

173 filaments were much thinner, a width similar to bacterial cells. Indeed, this quandary was not
174 resolved until the late 1950s when electron microscopy conclusively showed that the
175 actinomycete cellular structure was of a Gram-positive bacterial nature³⁹.

176
177 Central among actinomycetes, at least from a human perspective, are the
178 streptomycetes because they have yielded a remarkable number of useful natural products^{1-3, 6, 7,}
179 ⁴⁰. Historically, the suffix –mycin denotes a drug originally produced by a streptomycete. This
180 genus is also home to the model organism *Streptomyces coelicolor*, whose study has yielded
181 many key insights regarding natural product biosynthesis, as well as actinomycete development,
182 genetics, and genomics^{3, 28, 41, 42}.

183
184 Streptomycetes grow as a vegetative mycelium composed of many branching,
185 filamentous cells. When nutrients become limiting for vegetative growth, or in response to other
186 environmental cues, streptomycetes initiate a remarkable morphological developmental
187 process^{28, 42-44}. In many cases, as this transition occurs, growth of the vegetative mycelium is
188 curtailed or even undergoes what appears to be a programmed cell death event^{3, 45}. Around this
189 time is also when many natural product biosynthetic pathways are induced, and thus the
190 processes of morphological development and specialized metabolism are linked^{27, 42}.
191 Subsequently, aerial hyphae grow from the colony surface. A major checkpoint in this process is
192 the production of several proteins (eg rodmins and chaplins) and peptides (e.g. *sapB*) that coat
193 the surface of the aerial hypha resulting in a hydrophobic layer that is key to breaking the
194 surface tension at the colony/air interface^{42, 43, 46-49}. The distal end of the aerial hypha then
195 undergoes a concerted round of septation that results in the formation of many unigenomic
196 spores^{28, 44}. The spores are resistant to many environmental challenges including desiccation
197 and temperature extremes.

198
199 The genomes of actinomycetes are among the largest known for bacteria, often larger
200 than 8, or even 10 Mb^{5, 41}. In streptomycetes, the chromosome is usually linear, another feature
201 rarely found among bacteria. These genomes contain a central ‘core’ region of ~4-5 Mb that
202 contains all genes of essential function (though not all genes in the core are essential)⁵. Beyond
203 the edges of the core are the ‘arms’, which vary widely among actinomycetes in terms of their
204 gene content. Typically, more than 2/3 of the gene clusters involved in natural product
205 biosynthesis are found in the arm regions. For example, in *S. coelicolor*, the core contains
206 seven clusters for specialized metabolites, while the arms contain an additional twenty-one
207 clusters. Several excellent recent reviews of the metabolites produced by *S. coelicolor* are
208 available^{50, 51}.

209
210 Typical actinomycete genomes contain ~20 or more gene clusters dedicated to
211 specialized metabolism^{5, 39}. The most commonly found types of natural product gene clusters
212 encode for non-ribosomal peptide synthetases⁵² and polyketide synthases⁵³. In any given
213 actinomycete, only a fraction of these gene clusters is transcriptionally active under laboratory
214 conditions^{5, 7}. Recently, many research groups have begun exploring interspecies interactions
215 between bacteria, including actinomycetes, as a means for discovering novel compounds, and
216 as an initial attempt to gain insight into the ecological roles of these compounds.

217
218 As noted briefly above, in most actinomycetes, γ -butyrolactones serve as secreted
219 signaling molecules that govern the production of natural products³³. Once these signaling
220 molecules have achieved a high enough extracellular concentration, they interact with a
221 receptor protein, usually a transcriptional repressor, resulting in derepression of transcription of
222 the target biosynthetic genes. In *S. griseus* this appears to function in a way analogous to acyl-
223 homoserine lactone quorum sensing in Gram negative bacteria, with the signal molecule

224 gradually accumulating throughout the phase of active growth⁵⁴. However, in most other cases,
225 such as with *S. coelicolor*, the biosynthesis of γ -butyrolactone is limited to the transition to
226 stationary phase, and therefore correlates with nutrient limitation⁵⁵.

227
228 Classically, quorum sensing is thought to allow an organism to limit activities, such as
229 production of 'public goods' like secreted proteases or processes like biofilm formation, to
230 instances in which adequate biomass is present to make such coordinated activities
231 advantageous. For actinomycetes, production of specialized metabolites may also be beneficial
232 only if enough biomass is present. However, one might also speculate that placing antibiotic
233 production under control of a system that includes an extracellular signaling molecule could be a
234 way to test whether or not secreting an antibiotic into the surrounding environment is likely to be
235 effective. For example, if the extracellular signaling molecule never accumulates to a high
236 enough level, then it could indicate that diffusion in the surrounding environment is too great to
237 make antibiotic production a worthwhile strategy. One caveat to this hypothesis is that γ -
238 butyrolactones appear to exert their regulatory effects at nanomolar concentrations, while
239 antibiotics are typically effective at higher concentrations^{42, 55, 56}.

240

241

242 **B. Interactions involving antibiotic production**

243

244 In the past decade, multiple studies have included *S. coelicolor* in pairwise interactions
245 with other bacteria. In these studies, *S. coelicolor* has exhibited a wide range of phenotypes in
246 response to these interactions, and many of these responses involve the production of, or
247 response to different natural products (summarized in Fig. 1). Based on its genome, *S.*
248 *coelicolor* has the ability to produce 25 or more specialized metabolites, and among these
249 several have been studied extensively^{41, 50, 51}. These include the prodiginines, actinorhodins, the
250 calcium dependent antibiotic (CDA), coelimycin, methylenomycin, and a suite of siderophores
251 including the desferrioxamines and coelichelin. The prodiginines are a large family of red,
252 tripyrrole, cytotoxic pigments, and they include undecylprodigiosin and its cyclic derivative,
253 streptorubin B⁵⁷. The actinorhodins are blue antibiotic benzoisochromanquinone pigments, and
254 give *S. coelicolor* its name (*coelus*- sky + *color*- colored). CDA is a membrane-disrupting,
255 peptide-based antibiotic. Coelimycin is the recently described product of the "cryptic polyketide"
256 *cpk* biosynthetic cluster, and has relatively weak antibiotic activity⁵⁸. The antibiotic
257 methylenomycin is synthesized from genes encoded on the large, linear SCP1 plasmid, and are
258 notable because their production is regulated by a unique set of furan signaling molecules⁵⁹.
259 The desferrioxamines, the most common of which is desferrioxamine E, are hydroxamate-based
260 siderophores, and are widely produced by actinomycetes⁶⁰. Finally, coelichelin is a peptide-
261 based, mixed-ligand siderophore⁶¹.

262

263 Interactions with several other bacteria have been shown to stimulate *S. coelicolor* to
264 produce prodiginines, including *Bacillus subtilis*⁶² and multiple actinomycetes⁶³. This induction
265 was easily seen as red pigmentation in *S. coelicolor* colonies grown in proximity to colonies of
266 stimulating bacteria. Confirmation that prodiginines were produced in these cases was provided
267 by mass spectrometry (MS) techniques including matrix-assisted laser desorption/ionization
268 time-of-flight imaging (MALDI-TOF IMS)⁶², or nano-scale desorption electrospray ionization
269 (NanoDESI) coupled mass spectrometry⁶³. Luti and co-workers also demonstrated that heat-
270 killed cells of *B. subtilis* and *Staphylococcus aureus* greatly enhanced production of prodiginines
271 in *S. coelicolor* grown in bioreactors⁶⁴. In *Streptomyces lividans*, a very close relative of *S.*
272 *coelicolor*, it was found that red pigments (possibly a mixture of prodiginines and actinorhodins)
273 were produced in response to interactions with mycolic acid containing bacteria, including

274 *Tsukamurella pulmonis*, *Rhodococcus erythropolis*, and *Corynebacterium glutamicum*⁶⁵.
275 However, in none of these cases is it known how or why this induction occurs.
276

277 A recent study by Wang and co-workers found that sub-inhibitory doses of the
278 angucycline antibiotic jadomycin B, produced by *Streptomyces venezuelae*, was capable of
279 eliciting production of prodiginines in *S. coelicolor*⁶⁶. The authors demonstrated that this
280 regulation was mediated by the "pseudo" gamma-butyrolactone receptor ScbR2, which directly
281 binds jadomycin B, as well as actinorhodin and undecylprodigiosin, resulting in de-repression of
282 the prodiginine biosynthetic gene cluster. While this study did not show a direct interaction
283 between microbes, it is notable because it showed that production of one antibiotic
284 (prodiginines) can be stimulated by another antibiotic compound.
285

286 Production of prodiginines is not limited to the actinomycetes; various species of
287 *Serratia*⁶⁷, *Vibrio*, and *Hahella*⁶⁸ are also known to make these compounds (for a recent review
288 see⁶⁹). Prodiginines are known to have antitumor⁷⁰, antimalarial^{71, 72}, and immunosuppressant⁷³
289 activities and are in the process of being commercialized for cancer chemotherapy. Prodiginines
290 preferentially intercalate DNA at AT sites⁷⁴, and their reactivity with copper can lead to
291 subsequent radical cation formation and double-strand cleavage⁷⁵. In both *Serratia* and
292 *Streptomyces*, prodiginines usually remain associated with the producing cells^{76, 77}. This
293 association occurs at least in part due to the ability of the lipid tail of undecylprodigiosin to
294 interact with membrane lipids⁷⁸. Various roles/activities for prodiginines have been proposed
295 including decoupling of oxidative phosphorylation to dissipate excess ATP production^{79, 80},
296 scavenging of H₂O₂ generated by respiration or antibiotic exposure^{77, 81}, and protecting against
297 UV radiation^{77, 82}. Which of these roles, or other possible functions, is played by the prodiginines
298 in the interactions described above remain intriguing questions for future exploration. We note
299 that recently, Meschke and co-workers showed that prodiginines produced by *Streptomyces*
300 *lividans* had the ability to suppress the fungus *Verticillium dahliae* (the causative agent of
301 Verticillium wilt) on *Arabidopsis thaliana* roots⁸³. Thus, while the benefit of fungal suppression
302 gained by *S. lividans* remains to be examined, the prodiginines may have the potential to
303 mediate bacterial/fungal interactions in the rhizosphere.
304

305 Interactions with other bacteria can also stimulate production of actinorhodin in *S.*
306 *coelicolor*, including several species of *Bacillus*^{62, 84}, multiple actinomycetes⁶³, *Myxococcus*
307 *xanthus*⁸⁴, and *Serratia*⁸⁴. While these studies document that these interactions can stimulate
308 actinorhodin production, the mechanism(s) of this induction remains unknown. *M. xanthus* is a
309 predatory bacterium which actively lyses and consumes other bacteria through the action of
310 small molecules and secreted enzymes. Perez and co-workers⁸⁴ showed that *M. xanthus* is at
311 least somewhat capable of preying on *S. coelicolor*. They also suggest that the induction of
312 actinorhodin in *S. coelicolor* by *M. xanthus* might result in decreased motility of *M. xanthus*
313 toward *S. coelicolor* colonies, although more experiments are needed to quantify this effect.
314 Several species of *Pseudomonas*, including *P. fluorescens* and *P. aeruginosa* have been shown
315 to inhibit the production of γ -actinorhodin, the diffusible blue form of the compound, by *S.*
316 *coelicolor*⁸⁵. Specifically, the authors demonstrated that acidification via the production of
317 gluconic acid by the *Pseudomonas* strains inhibited the biosynthesis of γ -actinorhodin, while the
318 production of cell-associated actinorhodin (which is red) was unchanged.
319

320 Actinorhodin production is known to be regulated at a transcriptional level by numerous
321 physiological inputs, including DNA damage⁸⁶, *N*-acetylglucosamine⁸⁷, xylose⁸⁸, and nitrogen
322 availability⁸⁹. Encounters with other organisms in the soil (such as those described in the
323 previous paragraph) may trigger actinorhodin production by altering signaling through one of
324 these pathways. Likewise, production of both the actinorhodins and prodiginines are controlled

325 by multiple global regulators, such as AdpA⁹⁰, AbsA2^{91, 92}, and AbrC1⁹³, that coordinate
326 antibiotic biosynthesis. The physiological signals for these pathways remain largely unknown.
327 Thus, the study of interspecies interactions may provide a new experimental paradigm for
328 examining signaling through these poorly understood regulatory pathways.

329

330 C. Interactions involving siderophores

331

332 Siderophores are another major class of microbial natural products (reviewed in ⁹⁴).
333 These molecules are secreted by the producing organism into the surrounding environment,
334 where they effectively bind to iron. The iron-bound form of the molecule is then recognized and
335 imported by the producing organism as a means of uptaking iron. As siderophores are secreted
336 into the environment, they are vulnerable to piracy by other surrounding organisms that might
337 also have the receptor for a given iron-bound siderophore. As such, the possibilities for
338 siderophores to mediate interspecies interactions are many and diverse. Moreover, most
339 actinomycete genomes harbor three or more gene clusters for making siderophores, implying
340 that competition for iron in their natural habitats is commonplace⁶. One of the first studies to
341 examine interspecies interactions between streptomycetes found that stimulation of
342 development (observed as enhanced aerial hyphae formation) was a common outcome in a set
343 of ~60 strains⁹⁵. It was also found that many of these interactions resulted in enhanced
344 production of antibiotics, as detected by overlays with an indicator organism. In a subsequent
345 publication, these authors found that piracy of a siderophore, desferrioxamine, mediated these
346 interactions⁹⁶.

347

348 The desferrioxamine family of siderophores encompasses a broad range of molecules
349 whose production is commonplace among actinomycetes, based on genomic predictions^{6, 50}. In
350 fact, almost every streptomycete genome sequenced to date contains genes for their production.
351 Among streptomycetes, the most commonly produced versions of this siderophore are
352 desferrioxamines E, B, and G1⁹⁷. However, when challenged with five other actinomycetes, *S.*
353 *coelicolor* produced more than twelve analogs of the acyl-desferrioxamines, with fatty acid
354 appendages ranging from seven to seventeen carbons in length⁶³. Siderophores from the
355 competing strains, including amyachelin produced by *Amycolatopsis* sp. AA4, drove production of
356 this suite of siderophores by *S. coelicolor*. Sidebottom and co-workers found that many of these
357 molecules could be detected at low levels when *S. coelicolor* experienced iron limitation while
358 grown in rich medium⁹⁸. Thus, interspecies interactions that result in competition for iron can
359 drive the production of siderophores.

360

361 Another interaction involving siderophores was found when *S. coelicolor* aerial hyphae
362 development was inhibited by growth in proximity to another actinomycete *Amycolatopsis* sp.
363 AA4⁹⁹. This inhibition was the result of production of a siderophore, named amyachelin, produced
364 by the *Amycolatopsis*. It was found that the inhibition of development in *S. coelicolor* resulted
365 from iron limitation brought about by the chelating activity of amyachelin. In the same interactions,
366 it was found that *Amycolatopsis* was also capable of pirating desferrioxamines produced by *S.*
367 *coelicolor*. This and other recent studies have motivated an examination of the role of iron in
368 regulating development in actinomycetes^{100, 101}.

369

370 Beyond these examples, siderophores have been shown to mediate interactions
371 between other actinomycetes and plants¹⁰², *Bacillus*¹⁰³, and fungi (reviewed in¹⁰⁴). Recently
372 D'Onofrio et al showed that many environmental bacteria may depend on siderophores
373 produced by other organisms for their survival¹⁰⁵, implying that iron or siderophore
374 supplementation may open a new door to cultivating microbes from the soil.

375

376 **D. Frequency of interactions between actinomycetes**

377
378 How frequently do actinomycetes encounter each other in the soil environment? While
379 this question is experimentally challenging to address, several studies have examined the
380 frequency of interactions among actinomycetes on solid media. Kinkel and co-workers found
381 that *Streptomyces* strains inhibited other strains from the same (sympatric) soil population with
382 greater intensity (ie. growth inhibition zones were larger) compared to their ability inhibit isolates
383 from other (allopatric) soil populations¹⁰⁶. However, inhibition frequency was not enhanced
384 within isolates within sympatric populations compared to allopatric populations. Regarding
385 patterns of inhibition vs. resistance, Kinkel and co-workers also found that a strain's ability to
386 inhibit other strains was more highly variable than its resistance profile. And, strains typically
387 resisted others more frequently than they inhibited others. They noted that patterns of inhibition
388 and resistance were not correlated with phylogeny, but rather with niche overlap (as measured
389 by ability to utilize a panel of different carbon sources). This phenomenon was spatially specific,
390 ie. sympatric strains with high niche overlap inhibited each other more frequently than allopatric
391 strains with similar niche overlap. These observations suggest that antibiotic production is under
392 local selection, and that antibiotic production might mediate competition for nutrients. We note
393 that in this study, soil samples were collected in corers 10cm x 1cm; a relatively large size in
394 comparison to the microenvironments likely inhabited by microbes *in situ*.

395
396 Vetsigian and co-workers took a different approach in that they isolated several groups
397 of streptomycetes from individual soil grains, and examined interactions within and between
398 these groups of isolates¹⁰⁷. While they also found no correlation between positive or negative
399 interaction frequency and sympatry, they did find that interactions among isolates from the same
400 soil grain showed higher reciprocity. That is, if a 'sender' streptomycete inhibited a given
401 'receiver' strain, then the sender was likely to be inhibited by the receiver as well, but only if the
402 two isolates came from the same grain of soil. Similar to the study of Kinkel and co-workers¹⁰⁶,
403 they also observed that antibiotic production profiles differed more among genetically related
404 isolates than resistance profiles.

405 406 **4. Interactions involving *Bacillus***

407
408 *Bacillus subtilis* is a representative of an important group of soil bacteria. In addition to
409 being studied as a model Gram positive organism with regards to physiology and molecular
410 biology, *B. subtilis* has also been a key organism for the study of bacterial development (eg.
411 spore formation), multicellularity (eg. biofilm formation, swarming, etc), and interspecies
412 interactions.

413
414 During times of nutrient limitation, many *Firmicutes* undergo sporulation, which involves
415 a round of asymmetric cell division, yielding a small forespore (reviewed in ¹⁰⁸). The forespore is
416 then engulfed by the mother cell, and protective layers including a cortex and the inner and
417 outer coats are built around the forespore. The mother cell then lyses, freeing the mature spore.
418 This remarkable process involves a complex series of checkpoints and crosstalk between the
419 mother cell and forespore. Firmicute spores are arguably some of the most durable biological
420 structures. They are resistant to extremes in temperature, pH, radiation, and dessication, and
421 are viable for thousands, if not millions, of years ¹⁰⁹.

422
423 A large body of work has investigated the multicellular lifestyle of *B. subtilis* (recently
424 reviewed in ¹¹⁰⁻¹¹³). Most notably this includes formation of biofilms containing multiple cell types.
425 These types include cells dedicated to producing the extracellular biofilm matrix components,
426 flagellated motile cells, competent cells that take up exogenous DNA, cells that produce peptide

427 toxins, and cells destined for sporulation. While these various cell types have been examined
428 mostly in the context of growth on solid medium, one could imagine that the ability to
429 differentiate into multiple cell types could be vital in the context of an extremely heterogeneous
430 environment such as the soil. *B. subtilis* is also capable of making an extensive repertoire of
431 natural products (reviewed in ¹¹⁴) including lipopeptides¹¹⁵, polyketides^{116, 117}, and signaling
432 molecules¹¹⁰.

433

434 **A. Interactions that alter *B. subtilis* biofilm formation**

435

436 The many multicellular phenotypes of *B. subtilis* also offer a unique opportunity to
437 examine interspecies interactions mediated by natural products that alter complex microbial
438 behaviors (summarized in Fig. 2). Shank and co-workers took advantage of cellular variation in
439 a co-culture microcolony screen designed to identify other members of the soil microbiota that
440 interact with *B. subtilis*¹¹⁸. They started with a strain of *B. subtilis* with a fluorescent protein
441 under control of a promoter involved in biofilm matrix formation. They then plated this strain
442 along with an inoculum from soil on a plate containing 0.1x LB agar. This dilute medium served
443 to keep the colonies small, and insured that any activation of matrix production in *B. subtilis* was
444 a result of an interaction with a nearby colony of another species. Surprisingly, they found that
445 the most common inducers of biofilm formation were other members of the genus *Bacillus*.
446 These authors have recently found that a group of thiazolyl peptide antibiotics, the thiocillins,
447 was responsible for induction of matrix production genes in this interspecies context¹¹⁹.
448 Interestingly, they also found that structural alterations to the thiocillin molecule that abrogated
449 its antibiotic activity did not affect its ability to stimulate biofilm induction. This is intriguing as it
450 suggests that thiocillin possesses dual activities that can be structurally differentiated.

451

452 The ease of this screen makes it adaptable for looking for other interspecies interactions
453 that alter cellular differentiation¹²⁰. For example, by using different promoter fusions, one could
454 look for interactions that stimulate motility, competence, or sporulation. Beyond this, the results
455 of Shank and co-workers¹¹⁸ suggest that interactions that alter multicellularity may be
456 commonplace in the soil environment, and that these interactions may often occur between
457 members of the same genus. Previous work by Lopez and co-workers also showed that biofilm
458 formation in *B. subtilis* is also inducible by a suite of natural products including nystatin and
459 valinomycin¹²¹. These natural products all result in pore formation, raising the possibility that
460 potassium leakage (or subsequent potassium uptake) plays a role in activating biofilm formation
461 in *B. subtilis*. These results also suggest that interactions with other microbes, including
462 actinomycetes, have the potential to influence multicellular behaviors in *B. subtilis*.

463

464 **B. Natural products in *B. subtilis* interactions**

465

466 As both Firmicutes and actinomycetes are ubiquitous members of the soil community,
467 one might hypothesize that interactions between bacteria of these clades could be
468 commonplace and could involve alterations in the multicellular lifestyles of each. Indeed, in an
469 initial effort to examine potential interactions between *B. subtilis* and *S. coelicolor*, Straight and
470 co-workers found multiple knockout strains of *B. subtilis* that stimulated early production of
471 prodiginines in *S. coelicolor*¹²². These strains all had mutations in the *pks* cluster of *B. subtilis*,
472 which encodes the ability to make the specialized metabolite bacillaene¹¹⁶. Bacillaene is a linear,
473 heavily unsaturated molecule possessing two amide bonds, and a β -branch methyl group; a
474 unique set of features rarely seen in polyketides¹¹⁷. These findings were further substantiated by
475 Yang and co-workers, who used imaging mass spectrometry (IMS) to examine the *B. subtilis*/*S.*
476 *coelicolor* interaction⁶². They observed that bacillaene, and not surfactin or plipistatin, was
477 responsible for inhibiting prodiginine production, as well as several unknown molecules from *S.*

478 *coelicolor*. More recent work has found that swarming cells of *B. subtilis* do not make bacillaene,
479 and therefore stimulate prodiginine production in *Streptomyces lividans*¹²³. Only when cells
480 transition to a non-motile state, eg. they begin biofilm and sporulation processes, do they
481 express the *pks* gene cluster responsible for bacillaene production. Thus bacillaene production
482 is also tied to the multicellular differentiation program in *B. subtilis*. Exactly how bacillaene
483 inhibits prodiginine production in *S. coelicolor* remains unknown.
484

485 Recently, several interesting *B. subtilis* interactions with *M. xanthus* have also been
486 discovered. Müller and co-workers found that bacillaene protected *B. subtilis* from predation by
487 *M. xanthus*, and that *B. subtilis* spores were resistant to predation as well¹²⁴. The implication
488 from this work is that bacillaene production may afford *B. subtilis* time to sporulate during
489 predatory encounters with *M. xanthus*. These authors went on to find that in the course of being
490 preyed upon by *M. xanthus*, *B. subtilis* responds by forming megastructures composed of
491 sporulating cells and mature spores¹²⁵. Bacillaene production dictated the timing of
492 megastructure formation. Interestingly, formation of these megastructures did not require *B.*
493 *subtilis* biofilm components, suggesting that megastructure formation may be a unique
494 developmental trajectory. Taken together, these studies illustrate a key defensive role for
495 bacillaene, as it is capable of both inhibiting production of toxic molecules such as prodiginines
496 and CDA in nearby actinomycetes⁶², and in thwarting predation by *M. xanthus*¹²⁴.
497

498 The lipopeptide surfactin has also been shown to mediate many interactions between *B.*
499 *subtilis* and other bacteria, including actinomycetes. Surfactin, as its name suggests, possesses
500 surfactant properties and has been proposed to aid in *B. subtilis* signaling¹²⁶ and swarming
501 motility^{127, 128}. Surprisingly, surfactin produced by *B. subtilis* was found to inhibit aerial hyphae
502 formation in *S. coelicolor* and several other streptomycetes¹²⁹. This interference was
503 unexpected, since aerial hypha formation in streptomycetes is known to require surfactant
504 proteins and peptides, such as the RiPP SapB, to allow growth into the air. Straight and co-
505 workers also observed that transcription of the *ram* gene cluster (responsible for SapB
506 production) was enhanced in the presence of surfactin, but that no mature SapB could be
507 detected, suggesting that surfactin interferes with SapB posttranslational modification.
508 Consistent with this conclusion, imaging mass spectrometry confirmed that surfactin appeared
509 to inhibit production of SapB and, in addition, production of the calcium dependent antibiotic by
510 *S. coelicolor*⁶².
511

512 Building on these observations, Hoefler and co-workers showed that aerial hypha
513 formation in eight different streptomycetes was inhibited by surfactin¹³⁰. However, one strain,
514 *Streptomyces sp.* MG1, was barely affected, suggesting that it possessed a resistance
515 mechanism. Through IMS, they found that *Streptomyces sp.* MG1 secreted an enzyme with
516 surfactin hydrolase activity, SfhA, which cleaves the ester that forms the surfactin macrocycle.
517 Interestingly, SfhA can also cleave the *B. subtilis* product plipastatin, but not the streptomycete
518 products CDA or daptomycin. Thus, *Streptomyces sp.* MG1 is capable of not only a neutralizing
519 a compound that could adversely affect its ability to carry out its developmental program, but
520 also disrupting the ability of *B. subtilis* to engage in its own signaling and swarming behaviors.
521

522 In another noteworthy example of an enzyme/metabolite mediated interaction, Schneider
523 and co-workers observed that *B. subtilis* was able to inhibit both streptomycin production and
524 aerial hypha development in *Streptomyces griseus*¹³¹. They went on to show that *B. subtilis*
525 produced an enzyme, YtnP, capable of degrading the streptomycete signaling molecule γ -
526 butyrolactone. In *S. griseus*, both aerial hypha formation and streptomycin production require γ -
527 butyrolactone for their induction¹³². Finally, they also found that YtnP expression was induced by
528 sub-inhibitory doses of streptomycin. These observations suggest that upon sensing

streptomycin, *B. subtilis* can respond by making the enzyme YtnP, which can disrupt extracellular signaling in *S. griseus*. The final result is that both antibiotic production and development are curtailed. Thus, SfhA of *Streptomyces sp.* MG1, and YtnP of *B. subtilis* stand as two examples illustrating that the interplay between secreted enzymes and natural products can shape the outcome of microbial interspecies interactions.

5. Natural products in the evolutionary context of soil microbes

A. Are antibiotics signaling molecules?

The intriguing idea that antibiotics may play roles other than agents of interference competition has received substantial attention in recent years^{9, 12, 133-136}. This idea has grown with the realization that sub-inhibitory concentrations of antibiotics can activate differential transcriptional responses in bacteria. That is, the transcriptional pattern induced by an antibiotic at a low concentration is different than the pattern observed under a lethal dose^{10, 137-139}. In most cases, under sub-inhibitory concentrations, these responses involve genes in known stress response pathways, as well as processes that are seemingly unrelated to compound detoxification. It has been further suggested that antibiotics in natural environments may rarely reach the inhibitory concentrations familiar to biologists in the laboratory^{11, 136}. For example, under laboratory conditions, such as two microbial colonies growing on a petri plate, the numbers of bacteria present, and the amounts of antibiotics produced may far exceed levels seen in natural contexts. Moreover, in the clinical setting where the goal is to eradicate infection, the concentration of antibiotics used is necessarily high. Given these observations, it could be hypothesized that antibiotics have the capacity to function as signaling molecules in a natural environment such as the soil.

The question of the potential signaling role of antibiotics prompts a clear and concise consideration of relevant ecological terminology. To this end, we present Table 1, which defines several key terms in light of chemical interactions between bacteria. As noted by others before us^{140, 141}, these standard definitions originated from the study of animal interactions¹⁴², and they also form a useful framework for considering microbial interactions since each term has its own evolutionary implications. For example, for a chemical (e.g. antibiotic) to be a *bona fide* signal, it must have evolved in the sender due to its effect on the receiver, and the response of the receiver must benefit both itself and the sender. In contrast, a chemical cue has the ability to provoke a response in the receiver, but this response does not benefit the sender. Finally, chemical manipulation is a means by which the sender coerces a response in the receiver for its own benefit, at the detriment of the receiver.

	Definition	Beneficiary
Signal	A biosynthesized chemical that alters behavior in another organism because it has evolved to do so, and the receiver's response has also evolved.	Sender and Receiver
Cue	A biosynthesized chemical that alters behavior in another organism, however it did not evolve for that effect	Receiver
Coercion or Chemical Manipulation	A biosynthesized chemical that alters behavior in another organism, however the effect on the receiver is detrimental	Sender

Table 1. Proposed definitions for describing chemically-mediated interactions between bacteria.

What conditions are required for the evolution of intra- and interspecies signaling? These constraints have been reviewed elsewhere^{140, 141}, but are worth summarizing here as they are

569 relevant to many of the bacterial behaviors examined in this review. For intraspecies signaling
570 (e.g. quorum sensing) to evolve, several key conditions should be met: 1. the population should
571 contain individuals with high relatedness, 2. production of the signal should be of low cost to the
572 producer, and 3. the resulting benefit of the coordinated behavior should be high. Quorum
573 sensing in bacterial microcolonies meets all of these conditions as the population is made of
574 clonal individuals, the cost of making quorum molecules like the autoinducers of Gram negative
575 bacteria or γ -butyrolactones by actinomycetes is comparatively low, and lastly, the benefits of
576 quorum-regulated activities, like biofilm formation, virulence regulation, or antibiotic production
577 are presumably high¹⁴⁰.

578
579 For the evolution of interspecies signaling, two key criteria have been proposed¹⁴¹: 1.
580 high partner fidelity, and 2. the fitness of each partner must be dependent on the fitness of the
581 other. Thus, for the evolution of interspecies signaling, the organisms involved must reliably
582 associate with each other (likely over evolutionary time), and must mutually benefit from this
583 interaction. These types of relationships are most often seen in true symbiotic scenarios, such
584 as the endosymbionts within eukaryotic cells.

585
586 This review has presented many examples of microbial interspecies interactions that
587 involve natural products. Each of these examples could be considered in light of the framework
588 presented above. In most of these cases, not enough information is known to firmly categorize
589 these interactions. Possible examples of chemical manipulation might include the inhibition of
590 aerial hypha formation in *S. coelicolor* as a result of surfactin produced by *B. subtilis*¹²⁹, or
591 amyachelin produced by *Amycolatopsis* sp. AA4⁹⁹. However, we note that both surfactin and
592 amyachelin play distinct roles in the lives of their respective producing organisms that have little
593 to do with their abilities to interfere with aerial hyphae formation. Thus, these may simply be
594 examples of 'off target' effects.

595
596 In interactions where antibiotic production is stimulated, as with the prodiginines and
597 actinohrodins in *S. coelicolor* as a result of interactions with other actinomycetes⁶³, the actual
598 stimulus that prompts this antibiotic production is unknown. One simple possibility is that
599 competition for nutrients (i.e. exploitative competition) drives this stimulation, however, the fact
600 that only some interactions stimulate these phenotypes may argue against this possibility.
601 Moreover, because we do not know how the production of these molecules affect the
602 stimulating (or sender) organism, we cannot easily say if these interactions represent signaling,
603 cuing, or chemical manipulation.

604
605 Studies with purified molecules have the advantage that at least the stimulus for the
606 response is known. For example, sub-inhibitory doses of the antibiotic jadomycin B stimulated
607 the production of the prodiginines in *S. coelicolor* via the action of the "pseudo" gamma-
608 butyrolactone receptor ScbR2⁶⁶. In this case, hypothetically, *S. coelicolor* might encounter
609 jadomycin B being made by nearby cells of *S. venezuelae* and respond by making prodiginines.
610 In the simplest sense, this is likely a chemical cue. However, once again, it cannot be said with
611 certainty if jadomycin B is functioning as a signal, cue, or chemical manipulation agent, since
612 the effect of prodiginines on *S. coelicolor* and *S. venezuelae* are as yet undetermined.

613
614 In contrast, the work of Schnieder and co-workers presents a clear example of an
615 antibiotic cue. In this case, streptomycin produced by *S. griseus* is a cue for the production of an
616 enzyme, YtnP, in *B. subtilis*¹³¹. YtnP is capable of degrading γ -butyrolactone produced by the
617 streptomycete, thus disrupting the extracellular signaling cascade of *S. griseus*. Disrupting this
618 signaling cascade is advantageous for *B. subtilis* as it could curtail streptomycin production by *S.*
619 *griseus*.

620

621 Has a clear example of an antibiotic functioning as a signal molecule been described?

622 Given the framework outlined above, one is forced to conclude that a *bona fide* antibiotic signal

623 has yet to be demonstrated. The ecological definition of a signal sets a high bar, as determining

624 evolutionary 'intent' is difficult. However, while proving that an antibiotic is a signal is challenging,

625 there is ample evidence for antibiotic compounds serving as cues that drive diverse responses

626 among soil bacteria. Of course, many of the interactions examined in this review are likely to be

627 fragmentary. For example, in an interaction that stimulates production of prodiginines in *S.*628 *coelicolor*, those prodiginines could, in turn, be a cue or signal that drives the production of

629 another cue, etc. We are just at the beginning of understanding these networks, and much

630 remains to be discovered.

631

632 Does the soil offer the conditions necessary for interspecies signaling to evolve, i.e.

633 long-term, mutually beneficial associations between bacteria? One could easily imagine that in

634 an environment as heterogeneous and dynamic as the soil, interactions between and among

635 saprophytic bacteria (such as actinomycetes and *Bacilli*) might be transient and competitive in

636 nature. Organisms like plants that can inhabit the same location for an entire growing season or

637 many years offer a stable enough situation that such associations might develop. The many

638 symbiotic relationships documented between plants and fungi¹⁴³⁻¹⁴⁵, and plants and bacteria¹⁴⁶⁻639 ¹⁴⁹ attest to this possibility. Notably, much recent work suggests that actinomycetes^{102, 150-154} and640 firmicutes^{114, 155, 156} also have extended relationships with plants, and thus there exists the

641 possibility for interkingdom signaling between these organisms. If stable microbial communities

642 that include actinomycetes and firmicutes exist in the rhizosphere, then this might also offer a

643 stable environment conducive to evolution of interspecies signaling.

644

645 **B. Competition and evolutionary costs of specialized metabolism**

646

647 Among actinomycetes and *Bacilli*, the most common cue that induces production of648 specialized metabolites is cellular stress, often brought about by nutrient limitation^{27, 34, 157}. At

649 first this might seem counterintuitive. Why would a bacterium wait until its food supply was

650 depleted, or almost depleted, before starting to produce a natural product that requires the

651 synthesis of many proteins and drains metabolic intermediates from other processes? As

652 recently reviewed by Cornforth and Foster³⁴, ecologists have long categorized competition into653 two general types: *exploitative competition*, which occurs indirectly through competition for654 resources (e.g. food), and *interference competition*, which occurs when one organism directly655 harms another^{158, 159}.

656

657 From the time they were first discovered, antibiotics have been hypothesized to be

658 agents of interference competition, whereby the producer benefits from killing or inhibiting

659 nearby competitors⁸. However, the fact that many antibiotics are only produced in times of

660 stress suggests that exploitative competition may be the cue to initiate an interference strategy.

661 This idea, that microbes may use stress to ascertain the presence of other nearby microbes is

662 termed 'competition sensing' by Cornforth and Foster³⁴. This strategy of competition sensing

663 may reflect the fact that in natural environments, bacteria are (likely) always surrounded by

664 other microbes, and thus, nutrient limitation is the first indication that competition is about to

665 become fierce. In such a scenario, producing antibiotics at the onset of nutrient stress could be

666 a favorable strategy.

667

668 Extracellular signalling and multicellular development, two other hallmarks of

669 actinomycete and *Bacillus* lifestyles, are also connected to nutrient limitation and therefore

670 competition sensing^{28, 42, 113, 160}. As such, in times of nutrient stress, production of extracellular
671 signaling molecules may be a check to verify that enough cells are present to make the
672 coordinated production of antibiotics a favorable proposition. Concomitantly, one could
673 hypothesize that producing antibiotics might serve to buy enough resources and time to allow
674 the advancement of multicellular activities, like biofilm formation or aerial hypha development,
675 which ultimately culminate in sporulation (as seen with bacillaene production by *B subtilis* under
676 attack from *M. xanthus*¹²⁴). Moreover, as many antibiotics induce stress responses,
677 encountering these molecules in the soil may also serve as a cue to induce production of
678 antibiotics in kind²⁷. The many model systems examined in this review that involve co-culturing
679 of microbes may serve as excellent systems for systematically testing these hypotheses.
680

681 The widespread antibiotic resistance observed among actinomycetes¹⁶¹⁻¹⁶³ adds another
682 dimension to the considerations outlined above. If one microbe produces an antibiotic with the
683 aim of defending its 'territory', then it might be susceptible to resistant invaders. Likewise,
684 resistance would allow the continuation of multicellular development even in the presence of an
685 influx of antibiotics from nearby strains. These circumstances also prompt a consideration of the
686 relative costs and benefits of producing antibiotics and maintaining resistance. Many natural
687 product gene clusters contain 20-60 genes, and might occupy up to 80 kilobases of genomic
688 real estate^{6, 164}. In contrast, antibiotic resistance is often mediated by small operons containing
689 one or only a few genes. Thus, the cost of resistance is likely very small in comparison to the
690 cost of producing antimicrobial natural products. Perhaps it is not surprising then, that while
691 actinomycete most genomes may have 20-30 clusters for making natural products⁵, they can
692 also have upwards of 70 genes for antimicrobial resistance¹⁶⁵.
693

694 Ecological studies that have examined interactions among and between groups of
695 actinomycetes isolated from various soils may speak directly to these aspects of competition,
696 antibiotic production, and resistance. For example, Kinkel and co-workers¹⁰⁶ found that while
697 streptomycetes from the same soil sample tended to inhibit each other more strongly, there was
698 no correlation between sample site and resistance profile. In other words, the frequency of
699 resistance was the same in interactions between isolates from sympatric and allopatric
700 populations. This also suggests that antibiotic resistance is less costly compared to antibiotic
701 production. Moreover, the same study found that sympatric streptomycetes with similar carbon
702 source utilization patterns tended to inhibit each other more intensely, suggesting that
703 competition sensing and antibiotic production are closely linked. Consistent with this notion, Vaz
704 Jauri and co-workers found that interactions between actinomycetes that altered antibiotic
705 production were fairly common, with 35% of interactions either stimulating greater antibiotic
706 production or inhibiting antibiotic production¹⁶⁶.
707

708 In looking at a matrix of interactions among streptomycetes from several grains of soil,
709 Vetsigian and co-workers found that isolates tended to inhibit almost all other strains or almost
710 none¹⁰⁷. This implies that the outcome of such interactions is most often controlled by the
711 properties of the sender (i.e. the antibiotic producer) rather than the receiver. They also found
712 that different isolates with very high relatedness had very different patterns of inhibition,
713 indicating rapid evolution of antibiotic production patterns. Based on these network properties,
714 these researchers suggest streptomycete communities are not in an ecological stable state. In
715 other words, antibiotic production and resistance patterns have not resulted in an evolutionary
716 stalemate; rather these properties are undergoing constant adaptation.
717

718 A common theme in the studies by Vetsigian¹⁰⁷ and Kinkel¹⁰⁶ and co-workers is that the
719 ability to inhibit other streptomycetes is completely independent of strain phylogeny as
720 measured by 16S rRNA sequences. In fact, these observations further substantiated by similar


721 findings from Davelos Baines and co-workers who found that genotype did not predict antibiotic
722 production or resistance phenotypes¹⁶⁷. At an even larger, global scale, Schlatter and co-
723 workers found that *Streptomyces* isolate groups from six continents varied widely in their overall
724 ability to inhibit a test set of streptomycetes¹⁶⁸. And, isolates with near-identical 16S rRNA
725 sequences had little correlation in their antibiotic production, resistance, and resource utilization
726 capabilities. The fact that genetically related strains differ so much in their patterns of metabolite
727 production suggests that antibiotic biosynthetic capabilities; 1) are under intense local selection,
728 and 2) are dynamic over relatively short evolutionary timescales.

729


730 **Concluding remarks**

731

732 Studies that examine interactions between soil bacteria are beginning to shed light on
733 the many fascinating ways in which natural products can shape the outcome of these
734 encounters. These interactions can influence multicellular behavior and cellular differentiation,
735 life and death, and specialized metabolism. Clearly the heterogeneous and dynamic nature of
736 the soil environment, and interactions among its myriad of inhabitants, has shaped the
737 specialized metabolisms of the bacteria that live there. These specialized metabolisms, which
738 include an astounding array of useful natural products, are the result of constant and rapid
739 evolutionary processes that we are only beginning to understand. The many specialized
740 metabolites that can be made by a single actinomycete, for example, likely encompass a variety
741 of roles that we have yet to discover. We suggest that it is only through the study of interspecies
742 interactions that can we begin to understand these roles, and in turn, use this knowledge to
743 open new doors to discovery.



745
746 Fig 1. Interactions that influence natural product biosynthesis in *S. coelicolor*. Arrows indicate a
747 stimulatory relationship, flat ends indicate an inhibitory relationship. Arrow color indicates which
748 *S. coelicolor* molecule is influenced: red arrow = prodiginines, blue arrow = actinorhodin, purple
749 arrow = prodiginines and actinorhodins, green arrows = desferrioxamines. Note that the *S.*
750 *venezuelae* interaction has only been shown through in vitro addition of jadomycin B. SCB1 is a
751 gamma-butyrolactone whose production influences actinorhodin and prodiginine production.
752
753



754 Fig 2. Interactions involving *B. subtilis* and natural products. Arrows indicate a stimulatory
 755 relationship, flat ends indicate an inhibitory relationship. A flat end directed at an organism
 756 indicates growth inhibition, or predation in the case of *M. xanthus*. Bacillaene inhibits synthesis
 757 of calcium dependent antibiotic (CDA) and prodiginines by *S. coelicolor*. SfhA and YtnP are
 758 secreted enzymes. A-factor is the gamma-butyrolactone molecule that drives streptomycin
 759 production in *S. griseus*.
 760
 761

762 7. References

- 763
- 764 1. M. G. Watve, R. Tickoo, M. M. Jog and B. D. Bhole, *Arch Microbiol*, 2001, 176,
765 386-390.
- 766 2. J. Berdy, *J Antibiot (Tokyo)*, 2005, 58, 1-26.
- 767 3. K. F. Chater, *Philos Trans R Soc Lond B Biol Sci*, 2006, 361, 761-768.
- 768 4. K. Gerth, S. Pradella, O. Perlova, S. Beyer and R. Muller, *J Biotechnol*, 2003, 106,
769 233-253.
- 770 5. M. Nett, H. Ikeda and B. S. Moore, *Nat Prod Rep*, 2009, 26, 1362-1384.
- 771 6. G. L. Challis and D. A. Hopwood, *Proc Natl Acad Sci U S A*, 2003, 100 Suppl 2,
772 14555-14561.
- 773 7. R. H. Baltz, *Curr Opin Pharmacol*, 2008, 8, 557-563.
- 774 8. S. A. Waksman, *Bacteriol Rev*, 1941, 5, 231-291.
- 775 9. G. Yim, H. H. Wang and J. Davies, *Philos Trans R Soc Lond B Biol Sci*, 2007, 362,
776 1195-1200.
- 777 10. G. Yim, J. McClure, M. G. Surette and J. E. Davies, *J Antibiot (Tokyo)*, 2011, 64,
778 73-78.
- 779 11. J. Davies, G. B. Spiegelman and G. Yim, *Curr Opin Microbiol*, 2006, 9, 445-453.
- 780 12. D. Romero, M. F. Traxler, D. Lopez and R. Kolter, *Chem Rev*, 2011, 111, 5492-
781 5505.
- 782 13. I. M. Young and J. W. Crawford, *Science*, 2004, 304, 1634-1637.
- 783 14. J. W. Crawford, J. A. Harris, K. Ritz and I. M. Young, *Trends Ecol Evol*, 2005, 20,
784 81-87.
- 785 15. A. G. O'Donnell, I. M. Young, S. P. Rushton, M. D. Shirley and J. W. Crawford, *Nat*
786 *Rev Microbiol*, 2007, 5, 689-699.
- 787 16. C. Quince, T. P. Curtis and W. T. Sloan, *ISME J*, 2008, 2, 997-1006.
- 788 17. I. M. Young, and Ritz, K., *Soil and Tillage Research*, 2000, 53, 201-213.
- 789 18. J. Six, Bossuyt, H., Degryze, S. and Denef, K., *Soil and Tillage Research*, 2004, 79,
790 7-31.
- 791 19. M. Vos, A. B. Wolf, S. J. Jennings and G. A. Kowalchuk, *FEMS Microbiol Rev*, 2013,
792 37, 936-954.
- 793 20. D. S. Feeney, J. W. Crawford, T. Daniell, P. D. Hallett, N. Nunan, K. Ritz, M. Rivers
794 and I. M. Young, *Microb Ecol*, 2006, 52, 151-158.
- 795 21. A. B. Wolf, M. Vos, W. de Boer and G. A. Kowalchuk, *PLoS One*, 2013, 8, e83661.
- 796 22. J. L. Nadeau, N. N. Perreault, T. D. Niederberger, L. G. Whyte, H. J. Sun and R.
797 Leon, *Astrobiology*, 2008, 8, 859-874.
- 798 23. J. W. Crawford, L. Deacon, D. Grinev, J. A. Harris, K. Ritz, B. K. Singh and I. Young,
799 *J R Soc Interface*, 2012, 9, 1302-1310.
- 800 24. D. I. Andersson and D. Hughes, *Nat Rev Microbiol*, 2014, 12, 465-478.
- 801 25. S. R. Wegst-Uhrich, D. A. Navarro, L. Zimmerman and D. S. Aga, *Chem Cent J*,
802 2014, 8, 5.
- 803 26. J. R. Pils and D. A. Laird, *Environ Sci Technol*, 2007, 41, 1928-1933.
- 804 27. G. Liu, K. F. Chater, G. Chandra, G. Niu and H. Tan, *Microbiol Mol Biol Rev*, 2013,
805 77, 112-143.
- 806 28. K. Flardh and M. J. Buttner, *Nat Rev Microbiol*, 2009, 7, 36-49.

- 807 29. Y. Yamada, K. Sugamura, K. Kondo, M. Yanagimoto and H. Okada, *J Antibiot*
808 *(Tokyo)*, 1987, 40, 496-504.
- 809 30. S. Kitani, A. Iida, T. A. Izumi, A. Maeda, Y. Yamada and T. Nihira, *Gene*, 2008,
810 425, 9-16.
- 811 31. S. Kitani, K. T. Miyamoto, S. Takamatsu, E. Herawati, H. Iguchi, K. Nishitomi, M.
812 Uchida, T. Nagamitsu, S. Omura, H. Ikeda and T. Nihira, *Proc Natl Acad Sci U S A*,
813 2011, 108, 16410-16415.
- 814 32. E. Recio, A. Colinas, A. Rumbero, J. F. Aparicio and J. F. Martin, *J Biol Chem*, 2004,
815 279, 41586-41593.
- 816 33. E. Takano, *Curr Opin Microbiol*, 2006, 9, 287-294.
- 817 34. D. M. Cornforth and K. R. Foster, *Nat Rev Microbiol*, 2013, 11, 285-293.
- 818 35. B. A. Hense, C. Kuttler, J. Muller, M. Rothballer, A. Hartmann and J. U. Kreft, *Nat*
819 *Rev Microbiol*, 2007, 5, 230-239.
- 820 36. S. E. Darch, S. A. West, K. Winzer and S. P. Diggle, *Proc Natl Acad Sci U S A*, 2012,
821 109, 8259-8263.
- 822 37. W. C. Fuqua, S. C. Winans and E. P. Greenberg, *J Bacteriol*, 1994, 176, 269-275.
- 823 38. S. A. a. C. Waksman, R. E. , *Soil Science*, 1916, 1, 93-135.
- 824 39. D. A. Hopwood, *Annu Rev Genet*, 2006, 40, 1-23.
- 825 40. F. Zhu, C. Qin, L. Tao, X. Liu, Z. Shi, X. Ma, J. Jia, Y. Tan, C. Cui, J. Lin, C. Tan, Y.
826 Jiang and Y. Chen, *Proc Natl Acad Sci U S A*, 2011, 108, 12943-12948.
- 827 41. S. D. Bentley, K. F. Chater, A. M. Cerdeno-Tarraga, G. L. Challis, N. R. Thomson, K.
828 D. James, D. E. Harris, M. A. Quail, H. Kieser, D. Harper, A. Bateman, S. Brown, G.
829 Chandra, C. W. Chen, M. Collins, A. Cronin, A. Fraser, A. Goble, J. Hidalgo, T.
830 Hornsby, S. Howarth, C. H. Huang, T. Kieser, L. Larke, L. Murphy, K. Oliver, S.
831 O'Neil, E. Rabbinowitsch, M. A. Rajandream, K. Rutherford, S. Rutter, K. Seeger,
832 D. Saunders, S. Sharp, R. Squares, S. Squares, K. Taylor, T. Warren, A.
833 Wietzorrek, J. Woodward, B. G. Barrell, J. Parkhill and D. A. Hopwood, *Nature*,
834 2002, 417, 141-147.
- 835 42. J. M. Willey and A. A. Gaskell, *Chem Rev*, 2011, 111, 174-187.
- 836 43. D. Claessen, W. de Jong, L. Dijkhuizen and H. A. Wosten, *Trends Microbiol*, 2006,
837 14, 313-319.
- 838 44. J. R. McCormick and K. Flardh, *FEMS Microbiol Rev*, 2012, 36, 206-231.
- 839 45. H. Wildermuth, *J Gen Microbiol*, 1970, 60, 43-50.
- 840 46. K. F. Chater, S. Biro, K. J. Lee, T. Palmer and H. Schrempf, *FEMS Microbiol Rev*,
841 2010, 34, 171-198.
- 842 47. D. Claessen, R. Rink, W. de Jong, J. Siebring, P. de Vreugd, F. G. Boersma, L.
843 Dijkhuizen and H. A. Wosten, *Genes Dev*, 2003, 17, 1714-1726.
- 844 48. D. Claessen, I. Stokroos, H. J. Deelstra, N. A. Penninga, C. Bormann, J. A. Salas, L.
845 Dijkhuizen and H. A. Wosten, *Mol Microbiol*, 2004, 53, 433-443.
- 846 49. M. A. Elliot, N. Karoonuthaisiri, J. Huang, M. J. Bibb, S. N. Cohen, C. M. Kao and M.
847 J. Buttner, *Genes Dev*, 2003, 17, 1727-1740.
- 848 50. G. L. Challis, *J Ind Microbiol Biotechnol*, 2014, 41, 219-232.
- 849 51. G. van Keulen and P. J. Dyson, *Adv Appl Microbiol*, 2014, 89, 217-266.
- 850 52. M. A. Marahiel and L. O. Essen, *Methods Enzymol*, 2009, 458, 337-351.
- 851 53. J. Staunton and K. J. Weissman, *Nat Prod Rep*, 2001, 18, 380-416.
- 852 54. N. Ando, K. Ueda and S. Horinouchi, *Microbiology*, 1997, 143 (Pt 8), 2715-2723.

- 853 55. E. Takano, R. Chakraborty, T. Nihira, Y. Yamada and M. J. Bibb, *Mol Microbiol*,
854 2001, 41, 1015-1028.
- 855 56. S. Horinouchi, *Biosci Biotechnol Biochem*, 2007, 71, 283-299.
- 856 57. S. W. Haynes, P. K. Sydor, C. Corre, L. Song and G. L. Challis, *J Am Chem Soc*, 2011,
857 133, 1793-1798.
- 858 58. J. P. Gomez-Escribano, Song, L., Fox, D. J., Yeo, V., Bibb, M. J., and Challis, G. L.,
859 *Chemical Science*, 2012, 3, 2716-2720.
- 860 59. C. Corre, L. Song, S. O'Rourke, K. F. Chater and G. L. Challis, *Proc Natl Acad Sci U*
861 *SA*, 2008, 105, 17510-17515.
- 862 60. F. Barona-Gomez, U. Wong, A. E. Giannakopoulos, P. J. Derrick and G. L. Challis, *J*
863 *Am Chem Soc*, 2004, 126, 16282-16283.
- 864 61. S. Lautru, R. J. Deeth, L. M. Bailey and G. L. Challis, *Nat Chem Biol*, 2005, 1, 265-
865 269.
- 866 62. Y. L. Yang, Y. Xu, P. Straight and P. C. Dorrestein, *Nat Chem Biol*, 2009, 5, 885-
867 887.
- 868 63. M. F. Traxler, J. D. Watrous, T. Alexandrov, P. C. Dorrestein and R. Kolter, *MBio*,
869 2013, 4.
- 870 64. K. J. Luti and F. Mavituna, *Appl Microbiol Biotechnol*, 2011, 90, 461-466.
- 871 65. H. Onaka, Y. Mori, Y. Igarashi and T. Furumai, *Appl Environ Microbiol*, 2011, 77,
872 400-406.
- 873 66. W. Wang, J. Ji, X. Li, J. Wang, S. Li, G. Pan, K. Fan and K. Yang, *Proc Natl Acad Sci*
874 *USA*, 2014, 111, 5688-5693.
- 875 67. R. P. Williams, J. A. Green and D. A. Rappo-Port, *J Bacteriol*, 1956, 71, 115-120.
- 876 68. D. Kim, J. S. Lee, Y. K. Park, J. F. Kim, H. Jeong, T. K. Oh, B. S. Kim and C. H. Lee, *J*
877 *Appl Microbiol*, 2007, 102, 937-944.
- 878 69. N. Stankovic, L. Senerovic, T. Ilic-Tomic, B. Vasiljevic and J. Nikodinovic-Runic,
879 *Appl Microbiol Biotechnol*, 2014, 98, 3841-3858.
- 880 70. R. Perez-Tomas and M. Vinas, *Curr Med Chem*, 2010, 17, 2222-2231.
- 881 71. A. J. Castro, *Nature*, 1967, 213, 903-904.
- 882 72. V. H. Masand, D. T. Mahajan, K. N. Patil, T. B. Hadda, M. H. Youssoufi, R. D.
883 Jawarkar and I. G. Shibi, *Chem Biol Drug Des*, 2013, 81, 527-536.
- 884 73. S. B. Han, H. M. Kim, Y. H. Kim, C. W. Lee, E. S. Jang, K. H. Son, S. U. Kim and Y. K.
885 Kim, *Int J Immunopharmacol*, 1998, 20, 1-13.
- 886 74. M. S. Melvin, D. C. Ferguson, N. Lindquist and R. A. Manderville, *J Org Chem*,
887 1999, 64, 6861-6869.
- 888 75. G. Park, J. T. Tomlinson, M. S. Melvin, M. W. Wright, C. S. Day and R. A.
889 Manderville, *Org Lett*, 2003, 5, 113-116.
- 890 76. N. Kobayashi and Y. Ichikawa, *Microbiol Immunol*, 1989, 33, 257-263.
- 891 77. N. Stankovic, V. Radulovic, M. Petkovic, I. Vuckovic, M. Jadranin, B. Vasiljevic
892 and J. Nikodinovic-Runic, *Appl Microbiol Biotechnol*, 2012, 96, 1217-1231.
- 893 78. T. Sato, H. Konno, Y. Tanaka, T. Kataoka, K. Nagai, H. H. Wasserman and S.
894 Ohkuma, *J Biol Chem*, 1998, 273, 21455-21462.
- 895 79. D. W. Hood, R. Heidstra, U. K. Swoboda and D. A. Hodgson, *Gene*, 1992, 115, 5-
896 12.
- 897 80. H. Konno, H. Matsuya, M. Okamoto, T. Sato, Y. Tanaka, K. Yokoyama, T. Kataoka,
898 K. Nagai, H. H. Wasserman and S. Ohkuma, *J Biochem*, 1998, 124, 547-556.

- 899 81. M. Boric, T. Danevcic and D. Stopar, *Microb Ecol*, 2011, 62, 528-536.
- 900 82. R. Moeller, G. Horneck, R. Facius and E. Stackebrandt, *FEMS Microbiol Ecol*,
901 2005, 51, 231-236.
- 902 83. H. Meschke, S. Walter and H. Schrempf, *Environ Microbiol*, 2012, 14, 940-952.
- 903 84. J. Perez, J. Munoz-Dorado, A. F. Brana, L. J. Shimkets, L. Sevillano and R. I.
904 Santamaria, *Microb Biotechnol*, 2011, 4, 175-183.
- 905 85. J. Galet, A. Deveau, L. Hotel, P. Leblond, P. Frey-Klett and B. Aigle, *Arch*
906 *Microbiol*, 2014, 196, 619-627.
- 907 86. M. Iqbal, Y. Mast, R. Amin, D. A. Hodgson, W. Wohlleben and N. J. Burroughs,
908 *Nucleic Acids Res*, 2012, 40, 5227-5239.
- 909 87. S. Rigali, F. Titgemeyer, S. Barends, S. Mulder, A. W. Thomae, D. A. Hopwood
910 and G. P. van Wezel, *EMBO Rep*, 2008, 9, 670-675.
- 911 88. G. Y. Heo, W. C. Kim, G. J. Joo, Y. Y. Kwak, J. H. Shin, D. H. Roh, H. D. Park and I. K.
912 Rhee, *J Microbiol Biotechnol*, 2008, 18, 837-844.
- 913 89. R. Wang, Y. Mast, J. Wang, W. Zhang, G. Zhao, W. Wohlleben, Y. Lu and W. Jiang,
914 *Mol Microbiol*, 2013, 87, 30-48.
- 915 90. Y. Ohnishi, H. Yamazaki, J. Y. Kato, A. Tomono and S. Horinouchi, *Biosci*
916 *Biotechnol Biochem*, 2005, 69, 431-439.
- 917 91. N. L. Sheeler, S. V. MacMillan and J. R. Nodwell, *J Bacteriol*, 2005, 187, 687-696.
- 918 92. G. C. Uguru, K. E. Stephens, J. A. Stead, J. E. Towle, S. Baumberg and K. J.
919 McDowall, *Mol Microbiol*, 2005, 58, 131-150.
- 920 93. A. Yepes, S. Rico, A. Rodriguez-Garcia, R. I. Santamaria and M. Diaz, *PLoS One*,
921 2011, 6, e19980.
- 922 94. R. C. Hider and X. Kong, *Nat Prod Rep*, 2010, 27, 637-657.
- 923 95. K. Ueda, S. Kawai, H. Ogawa, A. Kiyama, T. Kubota, H. Kawanobe and T. Beppu, *J*
924 *Antibiot (Tokyo)*, 2000, 53, 979-982.
- 925 96. K. Yamanaka, H. Oikawa, H. O. Ogawa, K. Hosono, F. Shinmachi, H. Takano, S.
926 Sakuda, T. Beppu and K. Ueda, *Microbiology*, 2005, 151, 2899-2905.
- 927 97. M. Imbert, Bechet, M., and Blondeau, R., *Current Microbiology*, 1995, 31, 129-
928 133.
- 929 98. A. M. Sidebottom, A. R. Johnson, J. A. Karty, D. J. Trader and E. E. Carlson, *ACS*
930 *Chem Biol*, 2013, 8, 2009-2016.
- 931 99. M. F. Traxler, M. R. Seyedsayamdost, J. Clardy and R. Kolter, *Mol Microbiol*,
932 2012, 86, 628-644.
- 933 100. S. Lambert, M. F. Traxler, M. Craig, M. Maciejewska, M. Ongena, G. P. van Wezel,
934 R. Kolter and S. Rigali, *Metallomics*, 2014, 6, 1390-1399.
- 935 101. M. Craig, S. Lambert, S. Jourdan, E. Tenconi, S. Colson, M. Maciejewska, M.
936 Ongena, J. F. Martin, G. van Wezel and S. Rigali, *Environ Microbiol Rep*, 2012, 4,
937 512-521.
- 938 102. S. Rungin, C. Indananda, P. Suttiviriya, W. Kruasuwan, R. Jaemsang and A.
939 Thamchaipenet, *Antonie Van Leeuwenhoek*, 2012, 102, 463-472.
- 940 103. Y. L. Yang, Y. Xu, R. D. Kersten, W. T. Liu, M. J. Meehan, B. S. Moore, N. Bandeira
941 and P. C. Dorrestein, *Angew Chem Int Ed Engl*, 2011, 50, 5839-5842.
- 942 104. W. Wang, Z. Qiu, H. Tan and L. Cao, *Biometals*, 2014, 27, 623-631.
- 943 105. A. D'Onofrio, J. M. Crawford, E. J. Stewart, K. Witt, E. Gavrish, S. Epstein, J.
944 Clardy and K. Lewis, *Chem Biol*, 2010, 17, 254-264.

- 945 106. L. L. Kinkel, D. C. Schlatter, K. Xiao and A. D. Baines, *ISME J*, 2014, 8, 249-256.
- 946 107. K. Vetsigian, R. Jajoo and R. Kishony, *PLoS Biol*, 2011, 9, e1001184.
- 947 108. D. Higgins and J. Dworkin, *FEMS Microbiol Rev*, 2012, 36, 131-148.
- 948 109. W. L. Nicholson, N. Munakata, G. Horneck, H. J. Melosh and P. Setlow, *Microbiol*
949 *Mol Biol Rev*, 2000, 64, 548-572.
- 950 110. E. A. Shank and R. Kolter, *Curr Opin Microbiol*, 2011, 14, 741-747.
- 951 111. C. Aguilar, H. Vlamakis, R. Losick and R. Kolter, *Curr Opin Microbiol*, 2007, 10,
952 638-643.
- 953 112. D. Lopez, H. Vlamakis and R. Kolter, *FEMS Microbiol Rev*, 2009, 33, 152-163.
- 954 113. L. S. Cairns, L. Hobley and N. R. Stanley-Wall, *Mol Microbiol*, 2014, 93, 587-598.
- 955 114. J. Falardeau, C. Wise, L. Novitsky and T. J. Avis, *J Chem Ecol*, 2013, 39, 869-878.
- 956 115. K. Tsuge, T. Ano and M. Shoda, *Arch Microbiol*, 1996, 165, 243-251.
- 957 116. P. S. Patel, S. Huang, S. Fisher, D. Pirnik, C. Aklonis, L. Dean, E. Meyers, P.
958 Fernandes and F. Mayerl, *J Antibiot (Tokyo)*, 1995, 48, 997-1003.
- 959 117. R. A. Butcher, F. C. Schroeder, M. A. Fischbach, P. D. Straight, R. Kolter, C. T.
960 Walsh and J. Clardy, *Proc Natl Acad Sci U S A*, 2007, 104, 1506-1509.
- 961 118. E. A. Shank, V. Klepac-Ceraj, L. Collado-Torres, G. E. Powers, R. Losick and R.
962 Kolter, *Proc Natl Acad Sci U S A*, 2011, 108, E1236-1243.
- 963 119. R. Bleich, J. D. Watrous, P. C. Dorrestein, A. A. Bowers and E. A. Shank, *Proc Natl*
964 *Acad Sci U S A*, 2015, 112, 3086-3091.
- 965 120. E. A. Shank, *J Vis Exp*, 2013, e50863.
- 966 121. D. Lopez, M. A. Fischbach, F. Chu, R. Losick and R. Kolter, *Proc Natl Acad Sci U S*
967 *A*, 2009, 106, 280-285.
- 968 122. P. D. Straight, M. A. Fischbach, C. T. Walsh, D. Z. Rudner and R. Kolter, *Proc Natl*
969 *Acad Sci U S A*, 2007, 104, 305-310.
- 970 123. C. Vargas-Bautista, K. Rahlwes and P. Straight, *J Bacteriol*, 2014, 196, 717-728.
- 971 124. S. Muller, S. N. Strack, B. C. Hoefler, P. D. Straight, D. B. Kearns and J. R. Kirby,
972 *Appl Environ Microbiol*, 2014, 80, 5603-5610.
- 973 125. S. Muller, S. N. Strack, S. E. Ryan, D. B. Kearns and J. R. Kirby, *Appl Environ*
974 *Microbiol*, 2015, 81, 203-210.
- 975 126. D. Lopez, H. Vlamakis, R. Losick and R. Kolter, *Genes Dev*, 2009, 23, 1631-1638.
- 976 127. T. E. Angelini, M. Roper, R. Kolter, D. A. Weitz and M. P. Brenner, *Proc Natl Acad*
977 *Sci U S A*, 2009, 106, 18109-18113.
- 978 128. E. Ghelardi, S. Salvetti, M. Ceragioli, S. A. Gueye, F. Celandroni and S. Senesi,
979 *Appl Environ Microbiol*, 2012, 78, 6540-6544.
- 980 129. P. D. Straight, J. M. Willey and R. Kolter, *J Bacteriol*, 2006, 188, 4918-4925.
- 981 130. B. C. Hoefler, K. V. Gorzelnik, J. Y. Yang, N. Hendricks, P. C. Dorrestein and P. D.
982 Straight, *Proc Natl Acad Sci U S A*, 2012, 109, 13082-13087.
- 983 131. J. Schneider, A. Yepes, J. C. Garcia-Betancur, I. Westedt, B. Mielich and D. Lopez,
984 *Appl Environ Microbiol*, 2012, 78, 599-603.
- 985 132. J. Y. Kato, N. Funai, H. Watanabe, Y. Ohnishi and S. Horinouchi, *Proc Natl Acad*
986 *Sci U S A*, 2007, 104, 2378-2383.
- 987 133. A. Fajardo and J. L. Martinez, *Curr Opin Microbiol*, 2008, 11, 161-167.
- 988 134. J. Davies, *J Biotechnol*, 2007, 129, 3-5.
- 989 135. J. Davies, *J Antibiot (Tokyo)*, 2013, 66, 361-364.
- 990 136. G. Yim, H. H. Wang and J. Davies, *Int J Med Microbiol*, 2006, 296, 163-170.

- 991 137. G. Yim, F. de la Cruz, G. B. Spiegelman and J. Davies, *J Bacteriol*, 2006, 188,
992 7988-7991.
- 993 138. G. Yim, G. B. Spiegelman and J. E. Davies, *Res Microbiol*, 2013, 164, 416-424.
- 994 139. E. B. Goh, G. Yim, W. Tsui, J. McClure, M. G. Surette and J. Davies, *Proc Natl Acad*
995 *Sci U S A*, 2002, 99, 17025-17030.
- 996 140. S. P. Diggle, A. Gardner, S. A. West and A. S. Griffin, *Philos Trans R Soc Lond B*
997 *Biol Sci*, 2007, 362, 1241-1249.
- 998 141. L. Keller and M. G. Surette, *Nat Rev Microbiol*, 2006, 4, 249-258.
- 999 142. J. a. H. Maynard Smith, D., *Animal Signals*, Oxford University Press, New York,
1000 NY, 2003.
- 1001 143. F. Buscot, *J Plant Physiol*, 2015, 172C, 55-61.
- 1002 144. S. A. Ceasar, A. Hodge, A. Baker and S. A. Baldwin, *PLoS One*, 2014, 9, e108459.
- 1003 145. A. Hodge, *Adv Appl Microbiol*, 2014, 89, 47-99.
- 1004 146. M. Laranjo, A. Alexandre and S. Oliveira, *Microbiol Res*, 2014, 169, 2-17.
- 1005 147. B. Lugtenberg and F. Kamilova, *Annu Rev Microbiol*, 2009, 63, 541-556.
- 1006 148. C. W. Jin, Y. Q. Ye and S. J. Zheng, *Ann Bot*, 2014, 113, 7-18.
- 1007 149. G. Maroti and E. Kondorosi, *Front Microbiol*, 2014, 5, 326.
- 1008 150. V. M. Conn, A. R. Walker and C. M. Franco, *Mol Plant Microbe Interact*, 2008, 21,
1009 208-218.
- 1010 151. L. L. Kinkel, D. C. Schlatter, M. G. Bakker and B. E. Arenz, *Res Microbiol*, 2012,
1011 163, 490-499.
- 1012 152. N. A. Lehr, S. D. Schrey, R. Hampp and M. T. Tarkka, *New Phytol*, 2008, 177, 965-
1013 976.
- 1014 153. S. D. Schrey and M. T. Tarkka, *Antonie Van Leeuwenhoek*, 2008, 94, 11-19.
- 1015 154. M. T. Tarkka, N. A. Lehr, R. Hampp and S. D. Schrey, *Plant Signal Behav*, 2008, 3,
1016 917-919.
- 1017 155. P. B. Beauregard, Y. Chai, H. Vlamakis, R. Losick and R. Kolter, *Proc Natl Acad*
1018 *Sci U S A*, 2013, 110, E1621-1630.
- 1019 156. A. Perez-Garcia, D. Romero and A. de Vicente, *Curr Opin Biotechnol*, 2011, 22,
1020 187-193.
- 1021 157. T. Inaoka, K. Takahashi, M. Ohnishi-Kameyama, M. Yoshida and K. Ochi, *J Biol*
1022 *Chem*, 2003, 278, 2169-2176.
- 1023 158. L. C. Birch, *American Naturalist*, 1957, 91, 5-18.
- 1024 159. T. J. Case and M. E. Gilpin, *Proc Natl Acad Sci U S A*, 1974, 71, 3073-3077.
- 1025 160. H. Vlamakis, Y. Chai, P. Beauregard, R. Losick and R. Kolter, *Nat Rev Microbiol*,
1026 2013, 11, 157-168.
- 1027 161. J. A. Perry, E. L. Westman and G. D. Wright, *Curr Opin Microbiol*, 2014, 21C, 45-
1028 50.
- 1029 162. V. M. D'Costa, K. M. McGrann, D. W. Hughes and G. D. Wright, *Science*, 2006, 311,
1030 374-377.
- 1031 163. G. Dantas, M. O. Sommer, R. D. Oluwasegun and G. M. Church, *Science*, 2008,
1032 320, 100-103.
- 1033 164. M. A. Fischbach, C. T. Walsh and J. Clardy, *Proc Natl Acad Sci U S A*, 2008, 105,
1034 4601-4608.
- 1035 165. W. Zhao, Y. Zhong, H. Yuan, J. Wang, H. Zheng, Y. Wang, X. Cen, F. Xu, J. Bai, X.
1036 Han, G. Lu, Y. Zhu, Z. Shao, H. Yan, C. Li, N. Peng, Z. Zhang, Y. Zhang, W. Lin, Y.

- 1037 Fan, Z. Qin, Y. Hu, B. Zhu, S. Wang, X. Ding and G. P. Zhao, *Cell Res*, 2010, 20,
1038 1096-1108.
- 1039 166. P. Vaz Jauri and L. L. Kinkel, *FEMS Microbiol Ecol*, 2014, 90, 264-275.
- 1040 167. A. L. Davelos Baines, K. Xiao and L. L. Kinkel, *FEMS Microbiol Ecol*, 2007, 59,
1041 564-575.
- 1042 168. D. C. Schlatter and L. L. Kinkel, *FEMS Microbiol Ecol*, 2014, 88, 386-397.
- 1043
- 1044